About this Calculator

This guide provides clinical context for the Colchicine Dose Calculator. It outlines the tool’s parameters, explains the data it provides, and details the dosing principles for acute gout flares, gout prophylaxis, and Familial Mediterranean Fever (FMF). Dosing is adjusted based on key factors like renal function (eGFR) and significant drug-drug interactions.

Outputs Explained

The calculator provides a specific colchicine dosing recommendation based on the user’s inputs. The result includes:

• Recommended Dose: The precise medication strength and frequency (e.g., 1.2 mg PO once, followed by 0.6 mg in one hour).
• Input Summary: A confirmation of the parameters used for the calculation (e.g., Indication: Acute Gout, eGFR: < 30 mL/min/1.73m², Interaction: Strong).
• Clinical Rationale: A brief explanation of why the dose was chosen, highlighting adjustments made for renal impairment or drug interactions.
• Safety Note: A specific warning or monitoring parameter relevant to the calculated dose to prevent toxicity.

How to Use the Calculator

To ensure an accurate dosing recommendation, please provide the following patient information:

1. Indication: Select the primary reason for treatment (Treatment of Acute Gout Flare, Prophylaxis of Gout Flare, or Familial Mediterranean Fever).
2. Renal Function: You may either enter the patient’s most recent eGFR value directly or use the integrated calculator (2021 CKD-EPI equation) by providing the patient’s serum creatinine, age, and sex.
3. Concomitant Medications: Indicate if the patient is taking a strong CYP3A4/P-gp inhibitor (e.g., clarithromycin, ritonavir) or a moderate CYP3A4 inhibitor (e.g., diltiazem, verapamil), as these significantly alter colchicine metabolism.

Dosing Overview

Colchicine dosing must be individualized. The recommendations below reflect common adjustments based on major risk factors.

Treatment of Acute Gout Flare

• Standard Dose: 1.2 mg at the first sign of a flare, followed by 0.6 mg one hour later.
• With Moderate CYP3A4 Inhibitors: Dose is reduced to 1.2 mg as a single dose.
• With Strong CYP3A4/P-gp Inhibitors or eGFR <30: Dose is significantly reduced to 0.6 mg as a single dose. The treatment course should not be repeated more than once every 14 days in patients with severe renal impairment.

Prophylaxis of Gout Flare

• Standard Dose: 0.6 mg once or twice daily.
• With Moderate CYP3A4 Inhibitors: Dose should not exceed 0.6 mg/day.
• With Strong CYP3A4/P-gp Inhibitors: Dose reduced to 0.3 mg daily or every other day.
• With eGFR <30: Dose is typically reduced to 0.3 mg once daily.

Familial Mediterranean Fever (FMF)

• Standard Dose: 1.2 to 2.4 mg daily, administered in one or two divided doses.
• With Moderate CYP3A4 Inhibitors: Maximum daily dose is reduced to 1.2 mg.
• With Strong CYP3A4/P-gp Inhibitors: Maximum daily dose is reduced to 0.6 mg.
• With eGFR <30: The initial dose should be reduced to 0.6 mg daily, with cautious titration.

Switching or Adding Medications

If a patient on a stable colchicine dose starts a new medication that is a strong or moderate CYP3A4/P-gp inhibitor, the colchicine dose must be proactively reduced to prevent toxic accumulation. Conversely, if an interacting drug is discontinued, the colchicine dose may need to be adjusted upwards. Always consult official prescribing information before making changes.

Missed Dose

For patients on a daily colchicine schedule (prophylaxis or FMF), a missed dose should be taken as soon as it is remembered. If it is nearly time for the next scheduled dose, the missed dose should be skipped. Patients should not double their dose to make up for a missed one.

Safety Alerts

Colchicine has a narrow therapeutic index, and overdose can be life-threatening. Key safety considerations include:

• Toxicity: Early signs of toxicity include gastrointestinal symptoms (nausea, vomiting, diarrhea, abdominal pain). More severe toxicity can lead to myotoxicity (muscle pain/weakness), myelosuppression, and multi-organ failure.
• Renal and Hepatic Impairment: Use is contraindicated in patients with both renal and hepatic impairment. Significant dose adjustments are required for patients with severe renal impairment.
• Drug Interactions: Co-administration with drugs that inhibit CYP3A4 and/or P-glycoprotein can lead to fatal colchicine toxicity. This interaction risk is a primary focus of the calculator.

Frequently Asked Questions (FAQ)

1. What is the standard dose of colchicine for an acute gout attack?

The standard dosing regimen is 1.2 mg taken at the first sign of the flare, followed by 0.6 mg one hour later. This dose is adjusted for renal function and interacting medications.

2. Why is the colchicine dose reduced if my eGFR is below 30?

Colchicine is cleared by the kidneys. In severe renal impairment (eGFR < 30 mL/min/1.73 m²), the drug can accumulate to toxic levels, increasing the risk of severe side effects like myelosuppression. Therefore, a dose reduction is necessary.

3. I take diltiazem. How does this affect my colchicine dose?

Diltiazem is a moderate CYP3A4 inhibitor. It slows the breakdown of colchicine, increasing its concentration in the blood. For this reason, the maximum recommended dose of colchicine is typically reduced when taken with diltiazem.

4. The calculator recommended a very low dose (0.6 mg once) for my gout flare. Why?

This dose is recommended for patients with either severe renal impairment (eGFR < 30) or those taking a strong CYP3A4/P-gp inhibitor. Both conditions dramatically increase the risk of toxicity, making the low, single dose the safest effective option.

5. What is the maximum daily dose of colchicine for Familial Mediterranean Fever (FMF)?

For adults without interacting medications or severe renal impairment, the maximum daily dose is typically 2.4 mg. This maximum is reduced to 1.2 mg with moderate inhibitors and 0.6 mg with strong inhibitors.

6. Can I take colchicine if I am on dialysis?

Colchicine use in patients on dialysis is complex and generally requires significant dose reduction (e.g., 0.6 mg once for an acute flare, not to be repeated for 14 days). It should only be done under close medical supervision.

7. What are common examples of strong CYP3A4 inhibitors?

Examples include certain antibiotics (clarithromycin), antifungals (itraconazole, ketoconazole), and HIV protease inhibitors (ritonavir).

8. Is it safe to drink grapefruit juice while taking colchicine?

No. Grapefruit juice is a moderate inhibitor of CYP3A4 and can increase colchicine levels, raising the risk of toxicity. It should be avoided while taking colchicine.

References

1. COLCRYS® (colchicine) tablets prescribing information. U.S. Food and Drug Administration.
2. FitzGerald JD, et al. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Care Res (Hoboken). 2020.
3. Inker LA, Eneanya ND, Coresh J, et al. New Creatinine- and Cystatin C–Based Equations to Estimate GFR without Race. N Engl J Med. 2021.
4. Colchicine: Drug information. UpToDate. Wolters Kluwer.